Literature DB >> 22926077

Trauma patients' elevated tumor necrosis related apoptosis inducing ligand (TRAIL) contributes to increased T cell apoptosis.

Gautam Bandyopadhyay1, Paul E Bankey, Carol L Miller-Graziano.   

Abstract

Immunosuppression resulting from excessive post-trauma apoptosis of hyperactivated T cells is controversial. TRAIL mediated T cell apoptosis decreases highly activated T cells' responses. Caspase-10, a particular TRAIL target, was increased in trauma patients' T cells with concomitantly elevated plasma TRAIL levels. These patients' T cells developed anergy, implicating increased TRAIL-mediated T cell apoptosis in post-trauma T cell anergy. Control T cells cultured with patients' sera containing high TRAIL levels increased their caspase-10 activity and apoptosis. Stimulated primary T cells are TRAIL apoptosis resistant. Increased plasma thrombospondin-1 and T cell expression of CD47, a thrombospondin-1 receptor, preceded patients' T cell anergy. CD47 triggering of T cells increased their sensitivity to TRAIL-induced apoptosis. Augmentation of T cell TRAIL-induced apoptosis was secondary to CD47 triggered activation of the Src homology-containing phosphatase-1 (SHP-1) and was partially blocked by a SHP-1 inhibitor. We suggest that combined post-trauma CD47 triggering, SHP-1 mediated NFκB suppression, and elevated TRAIL levels increase patients' CD47 expressing T cell apoptosis, thus contributing to subsequent T cell anergy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926077      PMCID: PMC3448438          DOI: 10.1016/j.clim.2012.07.010

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  35 in total

1.  Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans.

Authors:  R S Hotchkiss; K W Tinsley; P E Swanson; R E Schmieg; J J Hui; K C Chang; D F Osborne; B D Freeman; J P Cobb; T G Buchman; I E Karl
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

2.  IFN-γ abrogates endotoxin tolerance by facilitating Toll-like receptor-induced chromatin remodeling.

Authors:  Janice Chen; Lionel B Ivashkiv
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

3.  Critical role of cRel subunit of NF-κB in sepsis survival.

Authors:  Emilie Courtine; Frédéric Pène; Nicolas Cagnard; Julie Toubiana; Catherine Fitting; Jessy Brocheton; Christophe Rousseau; Steve Gerondakis; Jean-Daniel Chiche; Fatah Ouaaz; Jean-Paul Mira
Journal:  Infect Immun       Date:  2011-02-22       Impact factor: 3.441

4.  Induction of global anergy rather than inhibitory Th2 lymphokines mediates posttrauma T cell immunodepression.

Authors:  A K De; K M Kodys; J Pellegrini; B Yeh; R K Furse; P Bankey; C L Miller-Graziano
Journal:  Clin Immunol       Date:  2000-07       Impact factor: 3.969

5.  Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1.

Authors:  Sukhbir Kaur; Svetlana A Kuznetsova; Michael L Pendrak; John M Sipes; Martin J Romeo; Zhuqing Li; Lijuan Zhang; David D Roberts
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

6.  Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression.

Authors:  Monika C Wolkers; Carmen Gerlach; Ramon Arens; Edith M Janssen; Patrick Fitzgerald; Ton N Schumacher; Jan Paul Medema; Douglas R Green; Stephen P Schoenberger
Journal:  Blood       Date:  2011-11-29       Impact factor: 22.113

7.  Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cells.

Authors:  Thomas S Griffith; Erik L Brincks; Prajwal Gurung; Tamara A Kucaba; Thomas A Ferguson
Journal:  J Immunol       Date:  2010-12-17       Impact factor: 5.422

8.  Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system.

Authors:  Hideki Okazawa; Sei-ichiro Motegi; Naoko Ohyama; Hiroshi Ohnishi; Takeshi Tomizawa; Yoriaki Kaneko; Per-Arne Oldenborg; Osamu Ishikawa; Takashi Matozaki
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

9.  TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways.

Authors:  Irena Stefanová; Bernhard Hemmer; Marco Vergelli; Roland Martin; William E Biddison; Ronald N Germain
Journal:  Nat Immunol       Date:  2003-02-10       Impact factor: 25.606

10.  The ability of protein tyrosine phosphatase SHP-1 to suppress NFkappaB can be inhibited by dominant negative mutant of SIRPalpha.

Authors:  Nickolay Neznanov; Lubov Neznanova; Roman V Kondratov; Donald M O'Rourke; Axel Ullrich; Andrei V Gudkov
Journal:  DNA Cell Biol       Date:  2004-03       Impact factor: 3.311

View more
  5 in total

Review 1.  Intestine immune homeostasis after alcohol and burn injury.

Authors:  Xiaoling Li; Adam M Hammer; Juan L Rendon; Mashkoor A Choudhry
Journal:  Shock       Date:  2015-06       Impact factor: 3.454

2.  Elevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells.

Authors:  Gautam Bandyopadhyay; Sanjukta Bandyopadhyay; Paul E Bankey; Carol L Miller-Graziano
Journal:  J Leukoc Biol       Date:  2014-07-07       Impact factor: 4.962

3.  Persistent lymphopenia is an independent predictor of mortality in critically ill emergency general surgical patients.

Authors:  P E Vulliamy; Z B Perkins; K Brohi; J Manson
Journal:  Eur J Trauma Emerg Surg       Date:  2015-10-26       Impact factor: 3.693

4.  Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice.

Authors:  Pulak R Nath; Dipasmita Pal-Nath; Sukhbir Kaur; Arunkumar Gangaplara; Thomas J Meyer; Margaret C Cam; David D Roberts
Journal:  Oncoimmunology       Date:  2022-09-06       Impact factor: 7.723

5.  Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine.

Authors:  David J Cain; Ana Gutierrez Del Arroyo; Gareth L Ackland
Journal:  Intensive Care Med Exp       Date:  2014-02-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.